Modification of a commercially available photoacoustic imaging system for the use of 1064nm and 532nm wavelengths
to assess photoacoustic contrast agents

Andrew Heinmiller; Kimberly Homan; Stanislav Emelianov; Adam Cole; Sanjiv Gambhir; Andrew Needles; Catherine Theodoropoulos; Desmond Hirson

doi:10.1117/12.2004804

4 March 2013 Modification of a commercially available photoacoustic imaging system for the use of 1064nm and 532nm wavelengths to assess photoacoustic contrast agents

Andrew Heinmiller, Kimberly Homan, Stanislav Emelianov, Adam Cole, Sanjiv Gambhir, Andrew Needles, Catherine Theodoropoulos, Desmond Hirson

Author Affiliations +

Proceedings Volume 8581, Photons Plus Ultrasound: Imaging and Sensing 2013; 85813O (2013) https://doi.org/10.1117/12.2004804
Event: SPIE BiOS, 2013, San Francisco, California, United States

Abstract

The use of near-infrared wavelengths for photoacoustic (PA) imaging takes advantage of the relatively low inherent absorption of tissues and has encouraged the development of agents which show high contrast in this range. Here, we describe the modification of a commercially available PA imaging system (Vevo LAZR, VisualSonics, Toronto) to take advantage of the 532nm and 1064nm wavelengths inherent in the generation of the currently tuneable range of 680 to 970nm and in the use of these two wavelengths to assess contrast agents. The photoacoustic imaging system generated light from a Nd/YAG laser modified to extract the 532 and 1064nm wavelengths in addition to its OPO-derived tuneable range (680 - 970 nm) and deliver this light through a fiber integrated into a linear array transducer (LZ400, VisualSonics). Gold nanorods (UT Austin), carbon nanotubes (Stanford U), DyLight 550 (Thermo Fisher) and blood were imaged in a phantom (PE20 tubing) and in a hindlimb subcutaneous tumor in vivo to determine their photoacoustic signal intensity at all wavelengths. In the phantom and in vivo, all agents caused an enhancement of the photoacoustic signal at their respective peak absorbance wavelengths. These results show that the 532nm and 1064nm wavelengths could prove useful in biomedical imaging due to the contrast agents customized for them. The 1064nm wavelength in particular has the advantage of having very low generation of endogenous signal in vivo, making agents tuned to this wavelength ideal for targeted contrast imaging.

Citation Download Citation

Andrew Heinmiller, Kimberly Homan, Stanislav Emelianov, Adam Cole, Sanjiv Gambhir, Andrew Needles, Catherine Theodoropoulos, and Desmond Hirson "Modification of a commercially available photoacoustic imaging system for the use of 1064nm and 532nm wavelengths to assess photoacoustic contrast agents", Proc. SPIE 8581, Photons Plus Ultrasound: Imaging and Sensing 2013, 85813O (4 March 2013); https://doi.org/10.1117/12.2004804

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
7 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Blood

Imaging systems

Photoacoustic spectroscopy

In vivo imaging

Photoacoustic imaging

Absorption

Tumors

Show All Keywords

Keywords/Phrases

Search In:

Publication Years